CalciMedica reported a net loss of $2.7 million for the first half of 2026, or $0.16 per share, compared to a $11.0 million loss in the prior year period. The company holds $18.6 million in cash and expects funding into late 2027. On June 24, 2026, CalciMedica completed a private placement raising up to approximately $49 million, including $15 million upfront, to advance its pulmonary hypertension strategy. The company plans a Phase 1b trial for Auxora in pulmonary arterial hypertension and anticipates an IND submission for oral candidate CM5480 in mid-2027. Additionally, the FDA aligned on the primary endpoint for the Phase 2b trial of Auxora in acute pancreatitis, which will measure reduction in new-onset severe respiratory failure. CalciMedica is a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies.
